The abstract is read at the publisher; the summary is JClub's.
In a Dutch nationwide cohort of 44,471 resected nonmetastatic colon cancer patients, only 57.8% of the 22,050 pathologically eligible for adjuvant chemotherapy initiated treatment.
- Why it matters: Guideline-recommended adjuvant chemotherapy improves outcomes in stage III and high-risk stage II disease, but real-world uptake and the drivers of variation are not well quantified at population level.
- What they did: Using Netherlands Cancer Registry data from 2005–2020, adults undergoing surgical resection were classified as ACT-eligible by Dutch guideline criteria (pT4N0 or node-positive), and adherence was measured as ACT initiation.
- The result: ACT was given to 2.6% of pathologically ineligible patients, while non-adherence was linked to advanced age, comorbidity, female sex, right-sided tumors, and non-elective surgery, with lower adherence in teaching/academic hospitals than general hospitals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.